MedTrace Logo

VYxeoS Liposomal Italian Observational Study iN the Real Practice

NCT06143839 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2025-11-20

No results posted yet for this study

Summary

The study is a prospective, single-arm, non-experimental, observational study in patients in Italy with Acute Myeloid Leukaemia (AML) with myelodysplastic-related changes or therapy related AML initiating treatment with JZP351 (Vyxeos liposomal) in their normal clinical practice.

Conditions

  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With Myelodysplasia-Related Changes
  • Therapy-Related Acute Myeloid Leukemia

Interventions

DRUG

Vyxeos liposomal

Standard of care JZP351 administered intravenously over 90 minutes.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-07
Primary Completion
2025-10-23
Completion
2025-10-23

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06143839 on ClinicalTrials.gov